Nojiri, Masafumi <br/><br/>
ADRB2 gene polymorphism and emphysema heterogeneity can modulate bronchodilator response in patients with emphysema.  [electronic resource] 

 -  Pulmonary pharmacology & therapeutics  02 2018 
 - 80-87 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1522-9629 
<br/><br/><label>Standard No.: </label>10.1016/j.pupt.2017.09.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Bronchodilator Agents--pharmacology<br/>Female<br/>Genetic Predisposition to Disease<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Polymerase Chain Reaction<br/>Polymorphism, Genetic<br/>Polymorphism, Restriction Fragment Length<br/>Procaterol--pharmacology<br/>Pulmonary Emphysema--drug therapy<br/>Receptors, Adrenergic, beta-2--genetics<br/>Tomography, X-Ray Computed